Endocrine Pharmacology Practice Questions

Q: Which of the following anti-diabetic drugs acts by inhibiting PPAR-gamma?

Thiazolidinediones. **Explanation:** **1. Why Thiazolidinediones (TZDs) are correct:** Thiazolidinediones (e.g., Pioglitazone, Rosiglitazone) are selective agonists for the **Peroxisome Proliferator-Activated Receptor-gamma (PPAR-γ)**, a nuclear receptor found primarily in adipose tissue, muscle, and liver. Activation of PPAR-γ regulates the transcription of genes involved in glucose and lipid metabolism. This leads to increased synthesis of GLUT-4 transporters and decreased free fatty acids, effectively **decreasing insulin resistance** (insulin sensitizers). **2. Why the other options are incorrect:** * **Sulfonylureas (e.g., Glipizide):** These act by blocking **ATP-sensitive K+ channels** on the pancreatic beta-cell membrane, leading to depolarization, calcium influx, and insulin exocytosis. They are insulin secretagogues, not PPAR-γ ligands. * **Biguanides (e.g., Metformin):** The primary mechanism is the activation of **AMP-activated protein kinase (AMPK)**, which inhibits hepatic gluconeogenesis and improves peripheral glucose uptake. * **Acarbose:** This is an **alpha-glucosidase inhibitor** that acts locally in the intestinal brush border to delay the digestion and absorption of carbohydrates, thereby reducing postprandial hyperglycemia. **3. High-Yield Clinical Pearls for NEET-PG:** * **Site of Action:** TZDs primarily act on **Adipose tissue** (different from Metformin, which primarily acts on the Liver). * **Side Effects:** Weight gain, **fluid retention/edema** (contraindicated in NYHA Class III/IV Heart Failure), and increased risk of bone fractures. * **Pioglitazone specific:** It also has some PPAR-alpha activity (improves lipid profile) but has been under scrutiny for a potential (though debated) risk of bladder cancer. * **Lag period:** The clinical effect of TZDs takes **6–12 weeks** to reach maximum potential because they work via gene transcription.

Q: Which insulin preparation has the longest duration of action?

Glargine. ### Explanation The duration of action of insulin preparations is determined by their rate of absorption from the subcutaneous tissue into the bloodstream. **Correct Answer: C. Glargine** Insulin Glargine is a **long-acting (basal) insulin analog**. It is designed to be soluble at an acidic pH (pH 4) but precipitates into micro-crystals upon injection into the neutral pH of subcutaneous tissue [1]. These crystals dissolve slowly, providing a relatively peakless, constant level of insulin for **up to 24 hours** [1]. This makes it ideal for maintaining basal glycemic control. **Why the other options are incorrect:** * **A & B (Aspart and Lispro):** These are **rapid-acting insulin analogs**. They are designed to dissociate rapidly into monomers after injection, leading to a quick onset (15 mins) and a very short duration of action (3–5 hours) [1]. They are used primarily for postprandial (mealtime) glucose control. * **D (NPH):** Neutral Protamine Hagedorn (NPH) is an **intermediate-acting insulin**. The addition of protamine delays its absorption, resulting in a duration of action of approximately 12–18 hours [1]. It has a distinct peak (4–10 hours), which increases the risk of nocturnal hypoglycemia compared to Glargine. **NEET-PG High-Yield Pearls:** * **Ultra-long acting:** If **Degludec** or **Glargine U-300** were options, they would be the correct answer as their duration exceeds 42 hours and 36 hours, respectively. * **Peakless Profile:** Glargine and Detemir are often called "peakless" insulins, reducing the risk of hypoglycemia [1, 2]. * **Mixing:** Glargine should **not** be mixed in the same syringe with other insulins because its low pH can cause the other insulin to precipitate. * **Inhaled Insulin (Afrezza):** Has the fastest onset of action among all preparations.

Q: A 37-year-old male patient diagnosed with sarcoidosis of the lung was treated with glucocorticoids. Glucocorticoids may result in bone loss primarily by which of the following mechanisms?

Inhibiting bone formation. **Explanation:** Glucocorticoid-induced osteoporosis (GIO) is the most common cause of secondary osteoporosis. The primary mechanism by which glucocorticoids cause bone loss is the **inhibition of bone formation**. **Why the correct answer is right:** Glucocorticoids exert a direct inhibitory effect on **osteoblasts** (bone-forming cells). They decrease osteoblast proliferation, reduce their differentiation from mesenchymal stem cells, and increase the apoptosis of both osteoblasts and osteocytes. This leads to a significant reduction in the bone formation rate. While they also transiently increase bone resorption, the sustained suppression of bone formation is the hallmark of glucocorticoid action on bone. **Why the incorrect options are wrong:** * **Option A:** Glucocorticoids actually **decrease** calcium absorption from the GI tract by antagonizing Vitamin D action. This leads to secondary hyperparathyroidism, further contributing to bone loss. * **Option B:** Glucocorticoids **inhibit** (rather than increase) osteoblast growth and activity. * **Option D:** Glucocorticoids **stimulate** bone resorption initially by increasing the expression of RANK ligand (RANKL) and decreasing Osteoprotegerin (OPG), which activates osteoclasts. **NEET-PG High-Yield Pearls:** * **Biphasic Pattern:** GIO has a rapid early phase (increased resorption) followed by a slower, chronic phase (decreased formation). * **Site Predilection:** Loss is most rapid in **trabecular bone** (e.g., vertebrae and ribs) compared to cortical bone. * **Clinical Management:** Bisphosphonates are the first-line treatment for prevention and therapy of GIO. * **Key Lab Finding:** Unlike primary osteoporosis, GIO often presents with low levels of biochemical markers of bone formation (e.g., serum osteocalcin).

Q: What is the primary drug of choice for the treatment of Addison's disease?

Hydrocortisone. **Explanation:** **Addison’s disease** (Primary Adrenocortical Insufficiency) is characterized by the deficiency of both glucocorticoids and mineralocorticoids. **Why Hydrocortisone is the Correct Answer:** Hydrocortisone (Cortisol) is the drug of choice because it is the **bio-equivalent of endogenous cortisol**. It possesses both glucocorticoid and significant mineralocorticoid activity (potency ratio 1:1). Its short duration of action allows for a "split-dose" regimen (e.g., 2/3rd in the morning and 1/3rd in the evening), which closely mimics the natural **circadian rhythm** of cortisol secretion. **Analysis of Incorrect Options:** * **Betamethasone:** This is a long-acting, highly potent glucocorticoid with **zero mineralocorticoid activity**. It is unsuitable for replacement therapy in Addison’s as it would not address the aldosterone deficiency and can cause severe suppression of the HPA axis. * **Prednisolone:** While it has some mineralocorticoid activity, it is primarily an intermediate-acting glucocorticoid. It is more commonly used for chronic inflammatory conditions rather than physiological replacement in Addison's. * **Deoxycorticosterone acetate (DOCA):** This is a pure mineralocorticoid. While it helps with salt retention, it lacks the glucocorticoid activity essential for glucose metabolism and stress response. **High-Yield Clinical Pearls for NEET-PG:** * **Fludrocortisone:** If hydrocortisone alone does not sufficiently manage electrolyte balance (hyponatremia/hyperkalemia), **Fludrocortisone** (a potent oral mineralocorticoid) is added to the regimen. * **Stress Dosing:** In patients with Addison’s, the dose of hydrocortisone must be **doubled or tripled** during periods of minor stress (fever, infection) and increased up to 10-fold during major surgery to prevent an **Addisonian Crisis**. * **Diagnosis:** The gold standard for diagnosis is the **ACTH Stimulation Test** (Cosyntropin test).

Q: Which among the following is not a SERM?

Flutamide. ### Explanation **Correct Answer: A. Flutamide** **1. Why Flutamide is the correct answer:** **Flutamide** is a non-steroidal **pure anti-androgen**, not a Selective Estrogen Receptor Modulator (SERM) [2]. It works by competitively inhibiting the binding of dihydrotestosterone (DHT) to androgen receptors. It is primarily used in the management of **prostate cancer** to block the effects of testosterone. **2. Analysis of Incorrect Options (SERMs):** SERMs are compounds that act as estrogen receptor agonists in some tissues (e.g., bone, liver) while acting as antagonists in others (e.g., breast, endometrium) [1]. * **B. Ormeloxifene (Centchroman):** A non-steroidal SERM developed in India (CDRI, Lucknow). It is used as a **once-a-week oral contraceptive** (Saheli) and for dysfunctional uterine bleeding. It has potent anti-estrogenic action on the uterus. * **C. Tamoxifen:** The "gold standard" SERM used in the treatment and prophylaxis of **ER-positive breast cancer** [1]. It acts as an antagonist in the breast but as an **agonist in the bone and endometrium** (increasing the risk of endometrial carcinoma) [1], [3]. * **D. Raloxifene:** A second-generation SERM used primarily for **postmenopausal osteoporosis** [1]. It acts as an agonist in the bone but, unlike tamoxifen, it is an **antagonist in the endometrium**, thus carrying no risk of uterine cancer [1]. **3. High-Yield Clinical Pearls for NEET-PG:** * **Clomiphene Citrate** is another SERM used for **ovulation induction** by inhibiting negative feedback at the hypothalamus [1]. * **Bazedoxifene** is a newer SERM used in combination with conjugated estrogens for menopausal symptoms. * **Toremifene** is a tamoxifen analogue with a similar profile used for metastatic breast cancer [1]. * **Mnemonic for Flutamide:** Remember "Flu-**T**-amide" for **T**estosterone/Androgen blockade.

Q: Which of the following is the drug of choice for the treatment of inappropriate anti-diuretic hormone secretion?

Demeclocycline. ### Explanation **Correct Answer: D. Demeclocycline** **Mechanism and Rationale:** Syndrome of Inappropriate Antidiuretic Hormone (SIADH) is characterized by excessive ADH release, leading to water retention and dilutional hyponatremia. **Demeclocycline**, a tetracycline derivative, is the drug of choice for chronic SIADH because it acts as an **ADH antagonist** at the level of the collecting duct. It induces a state of "nephrogenic diabetes insipidus" by interfering with the intracellular signaling (cAMP) triggered by ADH, thereby promoting the excretion of free water. **Analysis of Incorrect Options:** * **A. Furosemide:** While loop diuretics can be used in acute, symptomatic SIADH to increase free water clearance (usually alongside hypertonic saline), they are not the primary long-term treatment of choice. * **B. Hydrochlorothiazide:** Thiazides are contraindicated in SIADH. They inhibit sodium reabsorption in the distal tubule and can actually **worsen hyponatremia** by increasing ADH sensitivity and causing volume depletion-induced ADH release. * **C. Spironolactone:** This is a potassium-sparing diuretic (aldosterone antagonist) used primarily in hyperaldosteronism or heart failure; it has no role in antagonizing ADH. **High-Yield Clinical Pearls for NEET-PG:** * **Vaptans:** Tolvaptan (oral) and Conivaptan (IV) are "selective V2 receptor antagonists" and are now frequently preferred over demeclocycline for SIADH due to a better side-effect profile. * **Side Effect:** A major side effect of Demeclocycline is **nephrotoxicity** and photosensitivity. * **Correction Rate:** In SIADH, avoid rapid correction of hyponatremia to prevent **Osmotic Demyelination Syndrome** (Central Pontine Myelinolysis). Rule of thumb: <10–12 mEq/L in 24 hours. * **First-line treatment:** For mild/asymptomatic SIADH, the initial step is always **fluid restriction**.

Q: Which type of insulin is indicated in diabetic ketoacidosis?

Soluble insulin intravenously infusion. **Explanation:** **1. Why Soluble Insulin Intravenously is Correct:** Diabetic Ketoacidosis (DKA) is a medical emergency characterized by severe dehydration, acidosis, and hyperglycemia [4]. **Soluble (Regular) insulin** is the drug of choice because it is the only form that can be administered intravenously [3]. The IV route is preferred in DKA for two reasons: * **Rapid Onset:** It provides an immediate effect to suppress lipolysis and ketogenesis. * **Titratability:** It has a short half-life (approx. 5–10 minutes) when given IV, allowing clinicians to adjust the infusion rate precisely based on hourly blood glucose monitoring [1]. **2. Why Other Options are Incorrect:** * **Lente and Protamine Zinc Insulin (Options A & C):** These are intermediate and long-acting "cloudy" insulins. They contain particles (zinc or protamine) that delay absorption. They are strictly contraindicated for IV use as they can cause embolic phenomena and have a delayed onset, making them useless in an acute crisis. * **Subcutaneous Route (Options A & B):** In DKA, patients often suffer from peripheral circulatory collapse (shock) and dehydration [4]. Subcutaneous absorption becomes erratic and unpredictable in such states. Therefore, the IV route is mandatory until the patient is stable [3]. **3. High-Yield Clinical Pearls for NEET-PG:** * **Standard Protocol:** Low-dose IV insulin infusion (0.1 units/kg/hr) is the current standard of care [3]. * **The "Switch":** Transition to subcutaneous insulin only when the anion gap has closed and the patient is able to eat. * **Potassium Warning:** Insulin shifts potassium into cells. Always monitor K+ levels; if K+ is <3.3 mEq/L, delay insulin until potassium is replaced to avoid fatal arrhythmias [3][4]. * **Drug of Choice for Pregnancy:** Insulin remains the preferred agent for Gestational Diabetes Mellitus (GDM) [2].

Q: Which of the following drugs is a somatostatin analog?

Octreotide. No explanation text provided. **Explanation:** **1. Why Octreotide is correct:** **Octreotide** is a synthetic octapeptide analog of **somatostatin** (Growth Hormone Inhibiting Hormone) [1]. While natural somatostatin has a very short half-life (approx. 2 minutes), octreotide is much more potent and has a longer half-life (approx. 1.5 hours), making it clinically useful [1]. It acts by binding to somatostatin receptors (SSTR-2 and SSTR-5), leading to the inhibition of growth hormone (GH), glucagon, insulin, and various gastrointestinal hormones [2][3]. **2. Why the other options are incorrect:** * **Abarelix:** This is a **GnRH receptor antagonist** [5]. It is primarily used in the management of advanced prostate cancer to rapidly suppress testosterone levels without the initial "flare" seen with agonists [5]. * **Goserelin & Nafarelin:** These are **GnRH (Gonadotropin-Releasing Hormone) agonists**. While they initially stimulate FSH and LH, continuous administration leads to the downregulation of GnRH receptors, resulting in medical castration. They are used for endometriosis, precocious puberty, and prostate cancer. **3. High-Yield Clinical Pearls for NEET-PG:** * **Therapeutic Uses of Octreotide:** Acromegaly, secretory diarrheas (Carcinoid syndrome, VIPoma), and acute management of bleeding esophageal varices (by reducing splanchnic blood flow) [3][4]. * **Side Effects:** Biliary sludge and **gallstones** (due to inhibition of cholecystokinin and gallbladder contractility), steatorrhea, and nausea [3][4]. * **Other Analogs:** Lanreotide and Pasireotide (used specifically for Cushing’s disease) [2]. * **Mnemonic:** Remember **"S-O-L"** for Somatostatin analogs: **S**omatostatin, **O**ctreotide, **L**anreotide.

Question 1

Which of the following anti-diabetic drugs acts by inhibiting PPAR-gamma?

Accepted Answer

Thiazolidinediones

Answer

Sulfonylureas

Answer

Biguanides

Answer

Acarbose

Question 2

Which insulin preparation has the longest duration of action?

Accepted Answer

Glargine

Answer

Aspart

Answer

Lispro

Answer

NPH

Question 3

A 37-year-old male patient diagnosed with sarcoidosis of the lung was treated with glucocorticoids. Glucocorticoids may result in bone loss primarily by which of the following mechanisms?

Accepted Answer

Inhibiting bone formation

Answer

Increasing calcium absorption from the gastrointestinal tract

Answer

Increasing osteoblast growth

Answer

Inhibiting bone resorption

Question 4

Which of the following causes neutrophilia?

Accepted Answer

Glucocorticoids

Answer

Epinephrine

Answer

NSAIDs

Answer

Clozapine

Question 5

What is the primary drug of choice for the treatment of Addison's disease?

Accepted Answer

Hydrocortisone

Answer

Betamethasone

Answer

Prednisolone

Answer

Deoxycorticosterone acetate (DOCA)

Question 6

Which among the following is not a SERM?

Accepted Answer

Flutamide

Answer

Ormeloxifene

Answer

Tamoxifen

Answer

Raloxifene

Question 7

A young female presented with amenorrhea, infertility, and galactorrhea. She was treated with a drug that successfully restored ovulation and menstruation. The drug was administered orally. Which of the following drugs was most likely used to treat this patient?

Accepted Answer

Bromocriptine

Answer

Desmopressin

Answer

Human gonadotropin hormone

Answer

Leuprolide

Question 8

Which of the following is the drug of choice for the treatment of inappropriate anti-diuretic hormone secretion?

Accepted Answer

Demeclocycline

Answer

Furosemide

Answer

Hydrochlorothiazide

Answer

Spironolactone

Question 9

Which type of insulin is indicated in diabetic ketoacidosis?

Accepted Answer

Soluble insulin intravenously infusion

Answer

Lente insulin subcutaneously

Answer

Soluble insulin subcutaneously

Answer

Protamine zinc insulin intramuscularly

Question 10

Which of the following drugs is a somatostatin analog?

Accepted Answer

Octreotide

Answer

Abarelix

Answer

Goserelin

Answer

Nafarelin

Endocrine Pharmacology — MCQs

Endocrine Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?